enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Diabetic nephropathy - Wikipedia

   en.wikipedia.org/wiki/Diabetic_nephropathy

   Diabetic nephropathy is the most common cause of end-stage renal disease and is a serious complication that affects approximately one quarter of adults with diabetes in the United States. [ 13 ] [ 14 ] Affected individuals with end-stage kidney disease often require hemodialysis and eventually kidney transplantation to replace the failed kidney ...

3. These Diabetes Drugs Could Help Lower Your Risk of ... - AOL

   www.aol.com/diabetes-drugs-could-help-lower...

   According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood ...

4. A Common Drug Could Lower Your Dementia Risk By 35 ... - AOL

   www.aol.com/common-drug-could-lower-dementia...

   SGLT-2 inhibitors are a class of medications that treat type 2 diabetes. The medications help keep the kidneys from reabsorbing too much glucose and allow you to pee it out instead of circulating ...

5. A diabetes drug may help prevent dementia, new research shows

   www.aol.com/diabetes-drug-may-help-prevent...

   A recent study investigates how a diabetes medication may affect this risk. ... These drugs stop the kidneys from reabsorbing as much glucose, allowing the body to remove the glucose in urine ...

6. Nephrogenic diabetes insipidus - Wikipedia

   en.wikipedia.org/wiki/Nephrogenic_diabetes_insipidus

   The most obvious cause is a kidney or systemic disorder, including amyloidosis, [2] polycystic kidney disease, [3] electrolyte imbalance, [4] [5] or some other kidney defect. [ 2 ] The major causes of acquired nephrogenic diabetes insipidus that produce clinical symptoms (e.g., polyuria) in the adult are lithium toxicity and high blood calcium .

7. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.